Other News Topics (not Types of Cancer)

SWOG Launches National Immunotherapy Clinical Trial for Rare Cancers (03-23-2017)

People with rare cancers now have the option of joining a national clinical trial testing leading-edge immunotherapies for a wide variety of tumor types. It’s the first federally funded immunotherapy trial devoted to rare cancers. Despite their name,... Continue Reading

Dealing with Distress (03-17-2017)

Why it’s important to acknowledge distress during cancer care and what to do about it By Teresa L. Deshields and Clorinda Walley The moment a patient is diagnosed with cancer, one symptom is likely to surface: distress. Sadness, fear, helplessness,... Continue Reading

Xermelo-new option for controlling symptoms of Carcinoid Syndrome (03-1-2017)

The US Food and Drug Administration (FDA) today approved the oral therapy Xermelo (telotristat ethyl) to be used in combination with somatostatin analog (SSA) therapy for the treatment of adults with carcinoid syndrome diarrhea. Carcinoid syndrome is... Continue Reading

Cancer Connect Launches On line Community for Patients with Neuroendocrine Tumors (02-23-2017)

Sun Valley ID & Austin TX— OMNI Health Media (OMNI) announces the launch of a new online community on CancerConnect for individuals with neuroendocrine tumors (NET). This community will provide patients and their loved ones with information and... Continue Reading

It’s in the Genes: Genetic Testing Tutorial (10-7-2016)

Advances in genetic testing are offering women more information than ever before about their genetic makeup and are providing opportunities for empowered decision making related to a wide range of health issues. In this recurring column, experts provide... Continue Reading

Loxo Oncology Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for LOXO-101 (07-19-2016)

Loxo Oncology, Inc. (LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy... Continue Reading

Varubi Approved for Chemotherapy-Induced Nausea and Vomiting (09-21-2015)

The United States Food and Drug Administration (FDA) approved the agent Varubi (rolapitant) to be used to prevent delayed phase chemotherapy-induced nausea and vomiting (emesis). Chemotherapy-induced nausea and vomiting (CINV) is a common side effect... Continue Reading

Smoking Cessation Drug Not Boosting Number of Smokers Who Quit (08-19-2015)

The introduction of a new prescription smoking-cessation aid, varenicline, in 2006 has had no significant impact on the rate at which Americans age 18 and older successfully quit smoking, according to a study led by researchers at University of California,... Continue Reading

FDA Designates Breakthrough Therapy Designation for Azedra in Pheochromocytoma and Paraganglioma (08-12-2015)

The U.S. Food and Drug Administration (FDA) has designated Azedra as a Breakthrough Therapy for the treatment of patients with iobenguane-avid metastatic or recurrent pheochromocytoma and paraganglioma. Azedra is currently being evaluated in a pivotal... Continue Reading

theGIConnection and the Inflammatory Bowel Disease Support Foundation Partner to Provide Crohn’s Disease and Ulcerative Colitis Patients with Virtual Support Community (07-13-2015)

July 13, 2015 – Fort Worth TX/Sun Valley ID —OMNI Health Media (OMNI) and the Inflammatory Bowel Disease Support Foundation (IBDSF) are pleased to announce a partnership with TheGIConnection that will both improve access to and increase support... Continue Reading

« Previous PageNext Page »